The main outcome measures for this study were the presence of bacterial growth and the identification of the most commonly isolated bacteria from the cultures. We also tested the susceptibility of the isolates to selected antibiotics. Across all groups, we also looked at the proportions of patients with maternal signs of infection (i.e., tachycardia, fever, uterine tenderness, foul odor vaginal discharge), fetal tachycardia, stillbirth, and postpartum hemorrhage.
Statistical analysis
We used Epi Info™ 7.1.4.0 to analyze the data for this study. Continuous variables were summarized as means ± standard deviations and compared using ANOVA. Categorical variables were summarized as frequencies and percentages, and compared using chi-square. We set the level of significance at <0.05.
Results
A total of 120 patients were included in this analysis. Table 1 shows the baseline characteristics of the patients per exposure group. The three groups were comparable in terms of mean age, mean gravidity, and mean parity. The frequencies of elevated WBC and elevated CRP did not significantly differ across exposure groups.
Table 1
Patients’ characteristics on admission |
Characteristics |
6H* n=40 |
12H* n=40 |
18H* n=40 |
p-value |
Mean age ± SD, years |
25.40 ± 5.82 |
25.98 ± 5.98 |
26.35 ± 6.12 |
0.7742 |
Mean gravidity ± SD |
1.92 ± 1.49 |
1.73 ± 1.09 |
2.10 ± 1.93 |
0.5555 |
Mean parity ± SD |
0.74 ± 1.41 |
0.58 ± 0.78 |
0.98 ± 1.82 |
0.4430 |
Elevated WBC, frequency (%) |
1 (2.5) |
5 (12.5) |
4 (10.0) |
0.2422 |
Elevated CRP, frequency (%) |
6 (15.0) |
12 (30.0) |
10 (25.0) |
0.2713 |
|
Table 2 shows the comparative frequencies of outcomes of the three exposure groups. All groups were comparable in terms of prepartum symptoms. One patient from the 6H group had fetal tachycardia and one patient from the 12H group had maternal tachycardia. None of the patients in the study had maternal fever, uterine tenderness or foul odor vaginal discharge. One patient in the 12H group had stillbirth, and two patients in the 6H group had postpartum hemorrhage. However, none of the clinical outcomes had statistically significant difference in frequencies across the three groups. A total of 89/120 (74.17%) patients had positive placental swab cultures. The frequencies of positive placental swab cultures were similar across all groups (p=0.4986).
Table 2
Clinical outcomes |
Parameters |
Frequency (%) |
p-value |
6H* n=40 |
12H* n=40 |
18H* n=40 |
Maternal tachycardia |
0 |
1 (2.5) |
0 |
0.3648 |
Fetal tachycardia |
1 (2.5) |
0 |
0 |
0.3648 |
Fetal tachycardia |
1 (2.5) |
0 |
0 |
0.3648 |
Maternal fever |
0 |
0 |
0 |
1.0000 |
Uterine tenderness |
0 |
0 |
0 |
1.0000 |
Foul odor vaginal discharge |
0 |
0 |
0 |
1.0000 |
Postpartum hemorrhage |
2 (5.0) |
0 |
0 |
0.1308 |
Stillbirth |
0 |
1 (2.5) |
0 |
0.3648 |
Positive placental swab culture |
27 (67.5) |
31 (77.5) |
31 (77.5) |
0.4986 |
|
Isolates from the placental swab cultures are listed in Table 3. Across all groups, the five most common organisms isolated were Escherichia coli, Staphylococcus hominis, Staphylococcus haemolyticus, Staphylococcus epidermidis, and Enterobacter cloacae. One placental swab culture from the 6H group and another one from the 12H group grew methicillin-resistant Staphylococcus aureus (MRSA). The antibiotic susceptibility patterns of the five most common organisms and MRSA are summarized in Table 4.
Table 3
Bacterial isolates from patients with positive placental swab cultures |
6H* n=27 |
12H n=31 |
18H n=31) |
Organism† |
Frequency |
Organism† |
Frequency |
Organism† |
Frequency |
Escherichia coli |
8 |
Escherichia coli |
10 |
Escherichia coli |
10 |
Staphylococcus hominis |
4 |
Staphylococcus hominis |
4 |
Staphylococcus hominis |
3 |
Staphylococcus haemolyticus |
2 |
Enterobacter cloacae |
3 |
Acinetobacter spp. |
2 |
Staphylococcus epidermidis |
2 |
Staphylococcus epidermidis |
3 |
Bacillus spp. |
2 |
Bacillus spp. |
2 |
Staphylococcus haemolyticus |
3 |
Enterobacter cloacae |
2 |
Candida krusei |
1 |
Staphylococcus sciuri |
2 |
Klebsiella pneumoniae |
2 |
Enterobacter cloacae |
1 |
Pseudomonas putida |
2 |
Pseudomonas stutzeri |
2 |
Enterococcus faecalis |
1 |
Bacillus spp. |
1 |
Staphylococcus epidermidis |
2 |
Grimontia hollisae |
1 |
Klebsiella pneumoniae |
1 |
Staphylococcus haemolyticus |
2 |
Klebsiella pneumoniae |
1 |
Micrococcus luteus |
1 |
Acinetobacter lwoffii |
1 |
Kocuria kristinae |
1 |
MRSA |
1 |
Aeromonas spp. |
1 |
Kocuria rosea |
1 |
Pseudomonas mendocina |
1 |
Candida non-albicans |
1 |
Micrococcus luteus |
1 |
Staphylococcus aureus |
1 |
Enterococcus faecalis |
1 |
MRSA |
1 |
Staphylococcus capitis |
1 |
Staphylococcus warneri |
1 |
Staphylococcus aureus |
1 |
Staphylococcus warneri |
1 |
|
|
Staphylococcus capitis |
1 |
|
|
|
|
Staphylococcus epidermidis |
1 |
|
|
|
|
|
Table 4
Antibiotic susceptibility patterns for the five most common bacterial isolates and MRSA from 89 patients with positive placental swab cultures |
Antibiotic |
Escherechia coli |
Staphylococcus hominis |
Staphylococcus heamolyticus |
Staphylococcus epidermidis |
Enterobacter cloacae |
MRSA |
n* |
S |
I |
R |
n* |
S |
I |
R |
n* |
S |
I |
R |
n* |
S |
I |
R |
n* |
S |
I |
R |
n |
S |
I |
R |
Amikacin |
28 |
28 |
0 |
0 |
|
|
|
|
|
|
|
|
|
|
|
|
6 |
6 |
0 |
0 |
|
|
|
|
Ampicillin |
27 |
19 |
0 |
8 |
|
|
|
|
|
|
|
|
|
|
|
|
6 |
0 |
0 |
6 |
|
|
|
|
Ampi-sulbactam |
22 |
21 |
1 |
0 |
|
|
|
|
|
|
|
|
|
|
|
|
5 |
0 |
0 |
5 |
|
|
|
|
Azithromycin |
|
|
|
|
1 |
0 |
0 |
1 |
1 |
1 |
0 |
0 |
|
|
|
|
|
|
|
|
|
|
|
|
Aztreonam |
28 |
28 |
0 |
0 |
10 |
3 |
0 |
7 |
6 |
3 |
0 |
3 |
5 |
4 |
0 |
1 |
6 |
6 |
0 |
0 |
2 |
2 |
0 |
0 |
Cefepime |
28 |
28 |
0 |
0 |
|
|
|
|
|
|
|
|
|
|
|
|
6 |
6 |
0 |
0 |
|
|
|
|
Cefotaxime |
28 |
28 |
0 |
0 |
|
|
|
|
|
|
|
|
1 |
1 |
0 |
0 |
4 |
4 |
0 |
0 |
|
|
|
|
Cefoxitin |
28 |
28 |
0 |
0 |
11 |
3 |
0 |
8 |
7 |
1 |
0 |
6 |
6 |
2 |
0 |
4 |
6 |
0 |
0 |
6 |
2 |
0 |
0 |
2 |
Ceftazidime |
27 |
27 |
0 |
0 |
|
|
|
|
|
|
|
|
|
|
|
|
6 |
5 |
0 |
1 |
|
|
|
|
Ceftriaxone |
27 |
27 |
0 |
0 |
|
|
|
|
|
|
|
|
|
|
|
|
6 |
5 |
0 |
1 |
|
|
|
|
Cefuroxime |
28 |
28 |
0 |
0 |
|
|
|
|
|
|
|
|
|
|
|
|
6 |
2 |
0 |
4 |
|
|
|
|
Ciprofloxacin |
28 |
28 |
0 |
0 |
11 |
11 |
0 |
0 |
7 |
7 |
0 |
0 |
7 |
7 |
0 |
0 |
6 |
6 |
0 |
0 |
2 |
2 |
0 |
0 |
Clindamycin |
2 |
2 |
0 |
0 |
10 |
4 |
0 |
6 |
7 |
6 |
0 |
1 |
7 |
6 |
0 |
1 |
|
|
|
|
2 |
2 |
0 |
0 |
Coamoxiclav |
28 |
28 |
0 |
0 |
|
|
|
|
|
|
|
|
|
|
|
|
6 |
0 |
0 |
6 |
|
|
|
|
Cotrimoxazole |
24 |
16 |
0 |
8 |
11 |
8 |
0 |
3 |
7 |
5 |
0 |
2 |
7 |
4 |
0 |
3 |
6 |
4 |
0 |
2 |
2 |
1 |
0 |
1 |
Ertapenem |
28 |
28 |
0 |
0 |
|
|
|
|
|
|
|
|
|
|
|
|
6 |
5 |
0 |
1 |
|
|
|
|
Erythromycin |
|
|
|
|
11 |
8 |
0 |
3 |
7 |
4 |
0 |
3 |
7 |
4 |
0 |
3 |
|
|
|
|
2 |
2 |
0 |
0 |
Gentamicin |
27 |
27 |
0 |
0 |
11 |
11 |
0 |
0 |
7 |
7 |
0 |
0 |
7 |
6 |
0 |
1 |
6 |
6 |
0 |
0 |
2 |
2 |
0 |
0 |
Imipenem |
28 |
28 |
0 |
0 |
|
|
|
|
|
|
|
|
|
|
|
|
6 |
6 |
0 |
0 |
|
|
|
|
Levofloxacin |
26 |
26 |
0 |
0 |
11 |
11 |
0 |
0 |
7 |
7 |
0 |
0 |
6 |
6 |
0 |
0 |
6 |
6 |
0 |
0 |
2 |
2 |
0 |
0 |
Linezolid |
|
|
|
|
11 |
11 |
0 |
0 |
7 |
7 |
0 |
0 |
7 |
7 |
0 |
0 |
|
|
|
|
2 |
2 |
0 |
0 |
Meropenem |
28 |
28 |
0 |
0 |
|
|
|
|
|
|
|
|
|
|
|
|
6 |
6 |
0 |
0 |
|
|
|
|
Ofloxacin |
|
|
|
|
9 |
9 |
0 |
0 |
6 |
6 |
0 |
0 |
7 |
7 |
0 |
0 |
|
|
|
|
2 |
2 |
0 |
0 |
Oxacillin |
|
|
|
|
7 |
3 |
0 |
4 |
6 |
1 |
0 |
5 |
7 |
3 |
0 |
4 |
|
|
|
|
2 |
0 |
0 |
2 |
Penicillin |
|
|
|
|
11 |
1 |
0 |
10 |
7 |
0 |
0 |
7 |
7 |
3 |
0 |
4 |
|
|
|
|
2 |
0 |
0 |
2 |
Piperacillin |
12 |
11 |
1 |
0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Piper-tazo |
23 |
23 |
0 |
0 |
|
|
|
|
|
|
|
|
|
|
|
|
5 |
4 |
0 |
1 |
|
|
|
|
Rifampicin |
|
|
|
|
10 |
10 |
0 |
0 |
7 |
7 |
0 |
0 |
7 |
6 |
0 |
1 |
|
|
|
|
2 |
2 |
0 |
0 |
Tazobactam |
5 |
5 |
0 |
0 |
|
|
|
|
|
|
|
|
|
|
|
|
1 |
1 |
0 |
0 |
|
|
|
|
Tetracycline |
|
|
|
|
10 |
9 |
0 |
1 |
7 |
5 |
0 |
2 |
7 |
5 |
0 |
2 |
|
|
|
|
2 |
0 |
0 |
2 |
Tobramycin |
27 |
27 |
0 |
0 |
|
|
|
|
|
|
|
|
|
|
|
|
6 |
6 |
0 |
0 |
|
|
|
|
Vancomycin |
|
|
|
|
9 |
9 |
0 |
0 |
7 |
7 |
0 |
0 |
7 |
7 |
0 |
0 |
|
|
|
|
2 |
2 |
0 |
0 |
|
Discussion
Key results
In this study, the frequencies of bacterial growth in placental swab cultures did not significantly differ across exposure groups given ampicillin prophylaxis at different timings after term PROM. The most common bacterial isolates from the placental swab cultures were Escherichia coli, Staphylococcus hominis, Staphylococcus haemolyticus, Staphylococcus epidermidis, and Enterobacter cloacae.
Strengths and limitations
We were able to demonstrate bacterial growth in postpartum placental swab cultures from women who received ampicillin prophylaxis within 18 hours after term PROM. None of our patients developed clinical intraamniotic infection, but this finding underscores the importance of early administration of antibiotic prophylaxis to women with term PROM. There were some limitations in this study. Amniotic fluid culture is the gold standard for diagnosing intraamniotic infection,
11 but we did not include this as a study procedure. We only relied on postpartum placental swab culture to establish the presence of bacteria in the placenta, and yet we could not get data on bacterial loads of isolates, either. We did not include data on labor induction, and we did not account for the actual doses of ampicillin given to the patients and the time from PROM to delivery. These elements in the management of patients with term PROM can possibly affect bacterial growth in the placental swab cultures. Finally, apart from determining the presence of fetal tachycardia, we did not collect other parameters that can possibly establish the presence of fetal or neonatal infections related to PROM.
Interpretation
Term PROM is the rupture of membranes before labor at or after 37 weeks of gestation.
12 When labor is not induced, spontaneous delivery will usually occur in 70% of women within 24 hours and in 85% of women within 48 hours of rupture of membranes.
13 The condition can induce cord prolapse, cord compression, placental abruption, various deformities due to oligohydramnios, and/or mechanical difficulties during delivery.
14 15 Moreover, women with term PROM are at high risk of IAI.
14 16 17 Clinical IAI is diagnosed when a pregnant woman with PROM has fever, accompanied by at least two of the following: uterine tenderness, maternal or fetal tachycardia, and purulent or foul odor vaginal discharge.
18 19 In our study, none of our patients had clinical IAI. The administration of antibiotics on admission could have prevented any latent or clinical infection in at least some of our patients.
Antibiotics are generally recommended 18 hours after rupture of membranes.
20 21 Most pregnant women with term PROM in our institution all receive ampicillin prophylaxis upon admission, prior to delivery. We wanted to know if, despite administration of antibiotics, there would still be bacterial growth in postpartum placental swab cultures and, if there was, we wanted to check whether growth varied in frequency according to timing of antibiotic administration from the onset of rupture of membranes. Our results revealed that 67.5-77.5% of the placental swab cultures demonstrated bacterial growth despite pre-partum administration of ampicillin prophylaxis to women with PROM. Bacterial growth was present in cultures from placenta of women who were given antibiotic prophylaxis as early as <6 hours after rupture of membranes. The timing of antibiotic administration in relation to the onset of rupture of membranes did not significantly affect the proportion of patients with positive placental swab culture.
Intraamniotic infection after rupture of membranes usually happens through ascending bacterial invasion by aerobic and anaerobic organisms from the vagina.
17 Many organisms can cause infection of the placenta, but the most common are betahemolytic streptococci,
Staphylococcus aureus, Escherichia coli, and
Listeria monocytogenes.
22 23 24 Streptococcus viridans, Staphylococcus spp, Enterobacter cloacae, and
Gardnerella vaginalis have also been isolated in placenta from women who gave birth to preterm neonates.
25
In this study,
Escherichia coli turned out to be the most common organism isolated from the placenta, followed by
Staphylococcus hominis, Staphylococcus epidermidis, Staphylococcus haemolyticus and
Enterobacter cloacae. Two placental swab cultures also grew MRSA.
Escherichia coli and
Enterobacter cloacae are gram negative rods that are normally seen in the human intestine,
26 while
Staphylococcus epidermidis is part of the normal flora of the human skin, respiratory, and gastrointestinal tract,
27 but they can become pathogenic when they reach other tissues.
Routine prophylactic antibiotic administration to pregnant women at the time of term PROM can significantly reduce maternal and neonatal infectious morbidity.
28 However, judicious use of antibiotic should be ensured since there is an increasing incidence of bacterial resistance,
29 and—although rare—life-threatening maternal anaphylaxis with antibiotic use can occur.
30
In our institution, we usually use ampicillin as prophylactic antibiotic for women with term PROM. In this study, only 19 out of 27 Escherichia coli isolates were susceptible to ampicillin. Based on available data from the antibiotic susceptibility patterns of the five most common bacterial isolates from patients with positive placental swab cultures, the antibiotics that the organisms are most susceptible to are ciprofloxacin and levofloxacin. Four of the five organisms were also 100% susceptible to gentamicin. Quinolones like ciprofloxacin and levofloxacin are generally not used during pregnancy.
31 Both ciprofloxacin and levofloxacin are classified as Pregnancy Category C by the United States Food and Drug Administration.
32 Gentamicin can be combined with ampicillin to treat IAI.
33 This regimen is also useful in preventing or treating neonatal sepsis, which is a complication of PROM.
34 35
Generalizability
These results support the practice in our institution of giving antibiotic prophylaxis to pregnant women with term PROM upon admission. The antibiotic of choice should at least cover Escherichia coli, Staphylococcus spp. and Enterobacter cloacae, the most common bacterial isolates, and should be given as soon as possible, preferably within 18 hours from rupture of membranes. Obstetric practitioners in facilities similar to ours may consider our findings when managing pregnant women with term PROM who come to the facility right after rupture of membranes.
Conclusion
The rates of positive bacterial growth in placental swab cultures were similar across patient groups who received ampicillin prophylaxis at different timings (within 6 hours, more than 6 to 12 hours, and more than 12 hours to 18 hours) in relation to onset of term PROM. The most common bacteria isolated from the placental swab cultures were Escherichia coli, Staphylococcus hominis, Staphylococcus haemolyticus, Staphylococcus epidermidis, and Enterobacter cloacae.
In essence
Prelabor rupture of membranes during term pregnancy (term PROM) can cause maternal and neonatal infections.
In this study among women who received ampicillin prophylaxis within 18 hours of term PROM, the rates of positive bacterial growth in postpartum placental swab cultures were similar, regardless of timing of ampicillin administration.
Antibiotic prophylaxis for term PROM should at least cover common bacterial isolates—Escherichia coli, Staphylococcus spp. and Enterobacter cloacae—and should start within 18 hours from rupture of membranes.
Acknowledgments
We extend our heartfelt gratitude to the following: Dr Helen Grace Te-Santos for her guidance in the initiation of this research; Dr Maria Lourdes Cabling for her assistance during the conduct of this research; Dr Maria Elinore Concha, Dr Rojim Sorosa, and Dr Gilbert Vergara for their inputs in the design of this research; the laboratory staff and Obstetrics-Gynecology residents of Southern Philippines Medical Center for their participation in the implementation of this research; and Dr Lynnette Lasala, Dr Loida Michelle Ong, Mr Roel Ceballos, and Mr Clyde Vincent D Pacatang for their inputs during the preparation of this report.
Ethics approval
This study was reviewed and approved by the Department of Health XI Cluster Ethics Review Committee (DOH XI CERC reference P15072501).
Funding
Supported by personal funds of the authors
Competing interests
None declared
Access and license
This is an Open Access article licensed under the Creative Commons
Attribution-NonCommercial
4.0 International License, which allows
others to share and adapt the work, provided that derivative works
bear appropriate citation to this original work and are not used for
commercial purposes. To view a copy of this license, visit
https://creativecommons.org/licenses/by-nc/4.0/
References
1. Xia H, Li X, Liang H, Xu H. The clinical management and outcome of term premature rupture of membrane in East China: results from a retrospective multicenter study. Int J Clin Exp Med. 2015;8(4):6212-7.
2. Barišić T, Mandić V, Tomić V, Zovko A, Novaković G. Antibiotic prophylaxis for premature rupture of membranes and perinatal outcome. The Journal of Maternal-Fetal & Neonatal Medicine. 2017;30(5):580-4.
3. Cararach V, Botet F, Sentis J, Almirall R, Perez-Picanol E, onProm C. Administration of antibiotics to patients with rupture of membranes at term: A prospective, randomized, multicentric study. Acta Obstetricia et Gynecologica Scandinavica. 1998 Jan 1;77(3):298-302.
4. Passos F, Cardoso K, Coelho AM, Graca A, Clode N, Mendes da Graca L. Antibiotic prophylaxis in premature rupture of membranes at term: a randomized controlled trial. Obstet Gynecol. 2012;120(5):1045-51.
5. . Tran SH, Cheng YW, Kaimal AJ, Caughey AB. Length of rupture of membranes in the setting of premature rupture of membranes at term and infectious maternal morbidity. Am J Obstet Gynecol. 2008;198(6):700.e1-5.
6. Perez-Munoz ME, Arrieta MC, Ramer-Tait AE, Walter J. A critical assessment of the "sterile womb" and "in utero colonization" hypotheses: implications for research on the pioneer infant microbiome. Microbiome. 2017;5(1):48.
7. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep. 2002;51(Rr-11):1-22.
8. Saccone G, Berghella V. Antibiotic prophylaxis for term or near-term premature rupture of membranes: metaanalysis of randomized trials. Am J Obstet Gynecol. 2015;212(5):627.e1-9.
9. Nabhan AF, Elhelaly A, Elkadi M. Antibiotic prophylaxis in prelabor spontaneous rupture of fetal membranes at or beyond 36 weeks of pregnancy. Int J Gynaecol Obstet. 2014;124(1):59-62.
10. Norwitz ER, Greenberg JA. Antibiotics in Pregnancy: Are They Safe? Rev Obstet Gynecol. 2009;2(3):135-6.
11. Committee Opinion No. 712. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2017;130:e95–101.
12. Jazayeri A. Premature rupture of membranes. Medscape. 2017 December [cited 2017 December 31]. Available from: https://emedicine.medscape.com/article/261137-overview.
13. Keirse MJ, Ottervanger HP, Smit W. Controversies: prelabor rupture of the membranes at term: the case for expectant management. J Perinat Med. 1996;24(6):563-72.
14. Enkin M, Keirse MJ, Neilson J, Crowther C, Duler L, Hodnett E, et al. A guide to effective care in pregnancy and childbirth. 3rd ed. Oxford: Oxford University Press; 2000.
15. The Royal Australian and New Zealand College of Obstetricians and Gynecologists. Term prelabour rupture of membranes (term PROM) [Internet]. Melbourne; 2016 [cited 2017 December 31]. Available from: https://www.ranzcog.edu.au/RANZCOG_SITE/media/RANZCOG-MEDIA/Women%27s%20Health/Statement%20and%20guidelines/Clinical-Obstetrics/Term-Prelabour-Rupture-of-Membranes-(Term-Prom)-(C-Obs-36)-review-2017.pdf?ext=.pdf
16. Tran SH, Cheng YW, Kaimal AJ, Caughey AB. Length of rupture of membranes in the setting of premature rupture of membranes at term and infectious maternal morbidity. Am J Obstet Gynecol. 2008;198(6):700.e1-5.
17. American College of Obstetricians and Gynecologists. Intrapartum management of intraamniotic infection. Obstet Gynecol. 2017;130:e95–101.
18. Tita ATN, Andrews WW. Diagnosis and Management of Clinical Chorioamnionitis. Clin Perinatol. 2010;37(2):339-54.
19. Villar J, Papageorghiou A, Knight H, Gravett M, Iams J, Waller S, et al. The preterm birth syndrome: a prototype phenotypic classification. American Journal of Obstetrics and Gynecology. 2012;206(2):119-123.
20. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease: Revised guidelines from CDC. Centers for Disease Control and Prevention. 2002 August;51(RR11):1-22.
21. Kliegman R, Stanton B, Schor N, St. Geme J, Behrman R. Nelson textbook of Pediatrics. 19th ed. Philadelphia: Elsevier Saunders; 2011.
22. Sorano S, Goto M, Matsuoka S, Tohyama A, Yamamoto H, Nakamura S, et al. Chorioamnionitis caused by Staphylococcus aureus with intact membranes in a term pregnancy: A case of maternal and fetal septic shock. J Infect Chemother. 2016;22(4):261-4.
23. McClure EM, Dudley DJ, Reddy U, Goldenberg RL. Infectious causes of stillbirth: A clinical perspective. Clin Obstet Gynecol. 2010;53(3):635-45.
24. Bhola K, Al-Kindi H, Fadia M, Kent AL, Collignon P, Dahlstrom JE. Placental cultures in the era of peripartum antibiotic use. Aust N Z J Obstet Gynaecol. 2008 Apr;48(2)179-84.
25. Kornete A, Vedmedovska N, Blazuka S. Correlation between placental pathology and neonatal morbidity: a case-control study. Int J Reprod Contracept Obstet Gynecol. 2017 Feb:6(2):599-605.
26. Carroll K, Hobden J, Miller S, Morse S, Mietzner T, Detrick B, et al. Enteric Gram-Negative Rods (Enterobacteriaceae). In: Jawetz, Melnick, & Adelberg's Medical Microbiology. 27th ed. New York: McGraw-Hill; 2016. p. 231-246.
27. Carroll K, Hobden J, Miller S, Morse S, Mietzner T, Detrick B, et al. The Staphylococci. In: Jawetz, Melnick, & Adelberg's Medical Microbiology. 27th ed. New York: McGraw-Hill; 2016. p. 203-212.
28. Flenady V, King J. Antibiotics for prelabour rupture of membranes at or near term. The Cochrane Collaboration Database of Systematic Reviews. 2002.
29. Wojcieszek AM, Stock OM, Flenady V. Antibiotics for prelabour rupture of membranes at or near term. Cochrane Database of Systematic Reviews. 2014.
30. H. Heim K, Alge A, Marth C. Anaphylactic reaction to ampicillin and severe complication in the fetus. Lancet. 1991:337(8745):859-60.
31. Walker RC, Wright AJ. The fluoroquinolones. Mayo Clin Proc. 1991;66(12):1249-59.
32. Antibiotic use during pregnancy and lactation. Am Fam Physician. 2006 Sep;74(6):1035.
33. Stiglich N, Alston M, vanSwam S. Optimizing treatment of intra-amniotic infection and early-onset postpartum endometritis: advantages of single-agent therapy. Perm J. 2011;15(3):26-30.
34. Simonsen KA, Anderson-Berry AL, Delair SF, Davies HD. Early-onset neonatal sepsis. Clinical Microbiology Reviews. 2014;27(1):21-47.
35. National Collaborating Centre for Women's and Children's Health (UK). Antibiotics for early-onset neonatal infection: antibiotics for the prevention and treatment of early-onset neonatal infection. London: RCOG Press; 2012 Aug.
Copyright © 2017 M Corinales-Lomod, et al.